HAS opinions and decisions
La fiche de bon usage du médicament intitulée « Xolair (omalizumab) dans le traitement de l’asthme sévère», ci-jointe, est adoptée.
See also
HAS opinions and decisions
17/11/2017
eNrNWF1v2jAUfedXoLwnTqAlMAWqjrUrUtEYLdq0F2SSC5gZO/UH0P36OUA3mBJ1hFrqG+Q6517bx+eeOLraLGl1BUISztpO4PlOFVjME8JmbWf0eOs2natOJVrgFT4YZsZ5tZpTjSmWsu1kUW8CmEnve//+E5j3QTidSjXikwXE6micVoR6d1jO+zjNxlSjFSdJdQlqzpO2k2q1fVqNpBKmis6ai58yxTFEaP/kMLoYXxw+j1AG9h+oWoK4x2yWCwqsFGashQCmuljBjIvnXOhpPA5ql77fbJVKQeQQJNcihgFW84HgK5JAkp8JUwmlkkzXyQOIFQWVJckFR4t4KUuB4wXeDOGpl1/0tYl21Ua5vhuEwUW91QibYT0IS6USB0uVTx4zCZSO637YCFshAoYSiEnGcZfV/KDl+kG9gZIYpVTPCJOozxNN4e76IYsissQzkIjE3IRwmlJws99uw980fC89JtcJWzzgQmFqaXOJ7B7T1FIeAU+vkighMqX42VvItOxSYYFNGIQRE3sTyWbwKIy8UbNm/+AzTSk6serRXnwsVZxpW5drpgo06HZYdiG6nCnYFO9oOdlUmz0XCci3g/3FWX7LGOgJJXFZZTTapUGq0bBXLIzvUFM+YgkjYU9UvhGW8LV8e7E6JIel6tOt3uaCpiIJxrVWsxFcXpY+iz8MEwv63Y0WPAVkZIzIc9Spx6b8XF0y5M6HeqH2e2P11sPxGFMocHHjkkpn6PxiOq0dGHuHcRfIBf1881iWZV81iOeH7d9caJK0//CjXBuw0VsMpwsLP/2E7ITiNX9fa4YXzXqzHKVFvg7NlUrlB4TW67U3x9KV2CyWNxXvtd0cGAV7HylW3MjOne0k21Lpk10vPm2jy57b1/zKuR58//7e6+fmUELDGXuxk3hrQty7eXtt/2vArZU9ONIie2m2ZhkrIyi23Jee5Fuvs7qJ2Vd2K4xAfJlOScHdUSEvI7S7t+pUIpTdWXUqvwHPxkTv
0vayc5zzqZMMQ2L0